Stemergie Biotechnology ^None

Stemergie Biotechnology is a company that develops treatments and diagnostics for cancer by targeting cancer-initiating cells (CIC). The company was founded in 2009 as a spin-off from the Geneva University Hospital and the University of Geneva. Stemergie's proprietary methodology allows them to identify, isolate and enrich CIC independently of any marker. The company has identified and validated molecules that specifically eradicate brain CIC and plans to translate this technology to further types of CIC to treat and diagnose melanoma as well as other oncology indications. The company's treatments targeting the roots of cancer in combination with the current standard treatments have a high potential to increase the survival rate of the brain tumor patient in the future.